arrow
R

Rachael Lawrance

adelphi values
H指数:13
被引数:1,620

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Patient-reported outcomes with adjuvant nivolumab versus placebo after complete resection of stage IIB/C melanoma in the randomized phase 3 CheckMate 76 K trial

在随机III期CheckMate 76 K试验中,接受完全切除的IIB/C期黑色素瘤患者使用辅助纳武利尤单抗 versus 安慰剂治疗后的患者报告结局。

2025-05-010
OAAI
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes

一线nivolumab联合ipilimumab两周期化疗与单纯化疗 (四个周期) 治疗转移性非小细胞肺癌: CheckMate 9LA 2年患者报告的结果

2023-04-019
OAAI
Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial

Nivolumab联合ipilimumab与化疗作为具有高肿瘤突变负担的晚期非小细胞肺癌的一线治疗: 患者报告的结果来自随机,开放标签,III期CheckMate 227试验的结果

2019-07-01172
OAAI